The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

iwCLL 2017| Anti-CD19 CAR-T cell therapy with defined T-cell subsets for ibrutinib-refractory CLL

May 18, 2017

During iwCLL, on 15 thMay 2017, the “Additional Therapies for the Relapsed/Refractory CLL Patient” session took place and was co-chaired by Michael Keating( MD Anderson Cancer Center) and Jacqueline Barrientos( The Feinstein Institute for Medical Research).

“Anti-CD19 CAR-T Cell Therapy With Defined T-Cell Subsets for Ibrutinib-Refractory CLL” was a presentation given during this session by David G. Maloney, MD, PhD, from the Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Maloney began by explaining that CAR-T cells produced from distinct T-cell subsets differ in potency. NSG mice bearing Raji tumors (0.5x10 6tumor cell inoculation; day 0) were treated with human CAR-T cells manufactured from distinct T-cell subsets (on day 7). CAR-T cells produced from CD8 +T CMcells were highly potent ( Sommermeyer et al.2015).

Engineering selected T-cell subsets could enhance potency and allow delivery of the same cell product in all patients, potentially providing more uniform data on dose response and toxicity.

Pre-clinical studies have established that a defined composition of CD8 +T CMderived and CD4 +derived CAR T-cells provides optimal potency.

The talk then focused on the outline of the phase I/II study of JCAR014 in adult B-cell ALL, NHL, and CLL patients ( NCT01865617).

Study objectives:

  • Feasibility of manufacturing a defined composition CAR-T cell product
  • Safety of CD19 CAR-T cells
  • CAR-T cell persistence and migration
  • Anti-tumor efficacy in advanced B-cell malignancies

Patient eligibility:

  • R/R CD19+ B-cell malignancies (ALL, NHL, CLL)
  • ≥18 years of age
  • No inclusion/exclusion based on: ALC, circulating tumor, prior transplant, test expansion

As of 9/1/16, 136 patients had been treated: ALL = 48, NHL = 64, and CLL = 24.

Dose Level

Cells/kg

1

2x10 5EGFRt +

2

2x10 6EGFRt +

3

2x10 7EGFRt +

Lymphodepletion and JCAR014 immunotherapy in high-risk CLL patients:

Treatment

N=24

Lymphodepleting chemotherapy

Cyclophosphamide/fludarabine (Cy/Flu)

21 (87%)

Non-Cy/Flu

3 (13%)

CAR-T cell manufacturing

CD8+ central memory and CD4+

7 (29%)

CD8+ all subsets and CD4+

17 (71%)

CD19 CAR-T cell dose level

DL1 (2x10 5EGFRt +cells/kg)

4 (17%)

DL2 (2x10 6EGFRt +cells/kg)

19 (79%)

DL3 (2x10 7EGFRt +cells/kg)

1 (4%)

Cycles

Single cycle

18 (75%)

Outpatient lymphodepletion and CAR-T cells

18 (75%)

Second cycle for residual disease or relapse

6 (25%)

Maloney then asked “can IGH sequencing of the marrow at 4 weeks after JCAR014 identify patients with better outcomes?”

  • CR by iwCLL criteria requires all lymph nodes to be ≤15mm in longest axis
  • After JCAR014, 7/16 (44%) ibrutinib-refractory patients achieved PR by iwCLL
    • 4/5 (80%) with PET scans pre- and post-CAR-T cells had no FDG-avid disease
    • 4/6 (67%) were negative by IGH sequencing of the bone marrow

Additionally, higher JCAR014 counts in the blood after infusion were associated with better bone marrow response in high-risk CLL. Patients with a higher peak CD3+/EGFRt+ CAR-T cell count in the blood had a reduced hazard of progression or death (HR, 0.56; 95% CI, 0.34–0.93; P= 0.025).

Maloney concluded that in high-risk CLL patients CD19 CAR-T cells of defined composition (JCAR014) can be administered with an acceptable early toxicity profile. JCAR014 and Cy/Flu lymphodepletion shows a high-level or anti-tumor activity as measured by:

  • Bone marrow: clearance by flow cytometry in 15/17 (88%) and by IGHseq in 7/14 (50%)
  • iwCLL (at 4 weeks): ORR 14/19 (74%), CR 4/19 (21%)
  • PET-avid disease at baseline: CR (PET-negative): 7/11 (64%)

Deep marrow clearance by IGHseq after JCAR014 provides early signs of durable responses with 100% PFS and OS.

Lastly, Maloney presented evidence that ROR1 presents as a novel target for CAR-T cell therapy for CLL, MCL, and solid tumors as it is highly expressed on the surface of malignant B-cells:

  1. Maloney D.G.Anti-CD19 CAR-T Cell Therapy With Defined T-Cell Subsets for Ibrutinib-Refractory CLL. XVII International Workshop on Chronic Lymphocytic Leukemia; 2017 May 12–15; New York, USA.